Verona Pharma plc (VRNA) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 9 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for VRNA is $107.00, representing a +0.1% upside from the current price of $106.91. Price targets range from a low of $74.00 to a high of $170.00.
